Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Association Between Toll-Like Receptor 4 (TLR4) and Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Genetic Variants and Clinical Progression of Huntington's Disease.

Vuono R, Kouli A, Legault EM, Chagnon L, Allinson KS, La Spada A; REGISTRY Investigators of the European Huntington's Disease Network, Biunno I, Barker RA, Drouin-Ouellet J.

Mov Disord. 2020 Mar;35(3):401-408. doi: 10.1002/mds.27911. Epub 2019 Nov 14.

PMID:
31724242
2.

Choroid Plexus Acts as Gatekeeper for TREM2, Abnormal Accumulation of ApoE, and Fibrillary Tau in Alzheimer's Disease and in Down Syndrome Dementia.

Raha-Chowdhury R, Henderson JW, Raha AA, Vuono R, Bickerton A, Jones E, Fincham R, Allinson K, Holland A, Zaman SH.

J Alzheimers Dis. 2019;69(1):91-109. doi: 10.3233/JAD-181179.

3.

Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation.

Pircs K, Petri R, Madsen S, Brattås PL, Vuono R, Ottosson DR, St-Amour I, Hersbach BA, Matusiak-Brückner M, Lundh SH, Petersén Å, Déglon N, Hébert SS, Parmar M, Barker RA, Jakobsson J.

Cell Rep. 2018 Aug 7;24(6):1397-1406. doi: 10.1016/j.celrep.2018.07.017.

4.

Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.

Di Pardo A, Amico E, Basit A, Armirotti A, Joshi P, Neely MD, Vuono R, Castaldo S, Digilio AF, Scalabrì F, Pepe G, Elifani F, Madonna M, Jeong SK, Park BM, D'Esposito M, Bowman AB, Barker RA, Maglione V.

Sci Rep. 2018 May 24;8(1):8266. doi: 10.1038/s41598-018-23083-1.

5.

Dynamic and Cell-Specific DACH1 Expression in Human Neocortical and Striatal Development.

Castiglioni V, Faedo A, Onorati M, Bocchi VD, Li Z, Iennaco R, Vuono R, Bulfamante GP, Muzio L, Martino G, Sestan N, Barker RA, Cattaneo E.

Cereb Cortex. 2019 May 1;29(5):2115-2124. doi: 10.1093/cercor/bhy092.

PMID:
29688344
6.

Erythromyeloid-Derived TREM2: A Major Determinant of Alzheimer's Disease Pathology in Down Syndrome.

Raha-Chowdhury R, Henderson JW, Raha AA, Stott SRW, Vuono R, Foscarin S, Wilson L, Annus T, Fincham R, Allinson K, Devalia V, Friedland RP, Holland A, Zaman SH.

J Alzheimers Dis. 2018;61(3):1143-1162. doi: 10.3233/JAD-170814.

7.

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.

Di Pardo A, Amico E, Basit A, Armirotti A, Joshi P, Neely MD, Vuono R, Castaldo S, Digilio AF, Scalabrì F, Pepe G, Elifani F, Madonna M, Jeong SK, Park BM, D'Esposito M, Bowman AB, Barker RA, Maglione V.

Sci Rep. 2017 Jul 13;7(1):5280. doi: 10.1038/s41598-017-05709-y. Erratum in: Sci Rep. 2018 May 24;8(1):8266.

8.

REST suppression mediates neural conversion of adult human fibroblasts via microRNA-dependent and -independent pathways.

Drouin-Ouellet J, Lau S, Brattås PL, Rylander Ottosson D, Pircs K, Grassi DA, Collins LM, Vuono R, Andersson Sjöland A, Westergren-Thorsson G, Graff C, Minthon L, Toresson H, Barker RA, Jakobsson J, Parmar M.

EMBO Mol Med. 2017 Aug;9(8):1117-1131. doi: 10.15252/emmm.201607471.

9.

Neuroprotective Effect of TREM-2 in Aging and Alzheimer's Disease Model.

Raha AA, Henderson JW, Stott SR, Vuono R, Foscarin S, Friedland RP, Zaman SH, Raha-Chowdhury R.

J Alzheimers Dis. 2017;55(1):199-217.

PMID:
27662313
10.

Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease.

Breen DP, Nombela C, Vuono R, Jones PS, Fisher K, Burn DJ, Brooks DJ, Reddy AB, Rowe JB, Barker RA.

Mov Disord. 2016 Jul;31(7):1062-6. doi: 10.1002/mds.26592. Epub 2016 Mar 12.

11.

The role of tau in the pathological process and clinical expression of Huntington's disease.

Vuono R, Winder-Rhodes S, de Silva R, Cisbani G, Drouin-Ouellet J; REGISTRY Investigators of the European Huntington’s Disease Network, Spillantini MG, Cicchetti F, Barker RA.

Brain. 2015 Jul;138(Pt 7):1907-18. doi: 10.1093/brain/awv107. Epub 2015 May 6.

12.

Molecular and functional definition of the developing human striatum.

Onorati M, Castiglioni V, Biasci D, Cesana E, Menon R, Vuono R, Talpo F, Laguna Goya R, Lyons PA, Bulfamante GP, Muzio L, Martino G, Toselli M, Farina C, Barker RA, Biella G, Cattaneo E.

Nat Neurosci. 2014 Dec;17(12):1804-15. doi: 10.1038/nn.3860. Epub 2014 Nov 10.

PMID:
25383901
13.

Sleep and circadian rhythm regulation in early Parkinson disease.

Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, Barker RA.

JAMA Neurol. 2014 May;71(5):589-595. doi: 10.1001/jamaneurol.2014.65.

14.

Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons.

Delli Carri A, Onorati M, Lelos MJ, Castiglioni V, Faedo A, Menon R, Camnasio S, Vuono R, Spaiardi P, Talpo F, Toselli M, Martino G, Barker RA, Dunnett SB, Biella G, Cattaneo E.

Development. 2013 Jan 15;140(2):301-12. doi: 10.1242/dev.084608.

15.

Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens.

Ribeiro D, Laguna Goya R, Ravindran G, Vuono R, Parish CL, Foldi C, Piroth T, Yang S, Parmar M, Nikkhah G, Hjerling-Leffler J, Lindvall O, Barker RA, Arenas E.

Neurobiol Dis. 2013 Jan;49:118-27. doi: 10.1016/j.nbd.2012.08.006. Epub 2012 Aug 24.

PMID:
22940632
16.

Release of growth factors by neuronal precursor cells as a treatment for diseases with tau pathology.

Spillantini MG, Iovino M, Vuono R.

Arch Ital Biol. 2011 Jun;149(2):215-23. doi: 10.4449/aib.v149i1.1360. Erratum in: Arch Ital Biol. 2012 Mar;150(1):30.

PMID:
21701993
17.

Compound heterozygosity of 2 novel MAPT mutations in frontotemporal dementia.

Anfossi M, Vuono R, Maletta R, Virdee K, Mirabelli M, Colao R, Puccio G, Bernardi L, Frangipane F, Gallo M, Geracitano S, Tomaino C, Curcio SA, Zannino G, Lamenza F, Duyckaerts C, Spillantini MG, Losso MA, Bruni AC.

Neurobiol Aging. 2011 Apr;32(4):757.e1-757.e11. doi: 10.1016/j.neurobiolaging.2010.12.013. Epub 2011 Feb 3.

PMID:
21295377

Supplemental Content

Support Center